Shots:
- Mabwell has initiated a P-III trial of 9MW2821 in triple-negative breast cancer (TNBC), marking the fourth pivotal study for 9MW2821
- The trial will assess the efficacy of 9MW2821 vs the investigator’s choice chemotherapy in locally advanced or metastatic TNBC pts previously treated with taxane-based CT ± immunotherapy & a topoisomerase inhibitor-based ADC
- 9MW2821, a Nectin-4–targeting ADC, was being evaluated in the P-III trials in urothelial carcinoma & cervical cancer, with a US trial in ADC-treated TNBC initiated & first patient dosed in Aug 2025
Ref: PRnewswire | Image: Mabwell | Press Release
Related News: Mabwell Doses First US Patient in P-I/II Trial of 7MW4911 for Gastrointestinal (GI) Cancers
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
